Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected to Post Earnings of -$0.73 Per Share

Analysts expect that Travere Therapeutics, Inc. (NASDAQ:TVTX) will report earnings per share of ($0.73) for the current quarter, according to Zacks. Four analysts have made estimates for Travere Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.68) and the lowest estimate coming in at ($0.79). Travere Therapeutics posted earnings per share of ($0.58) in the same quarter last year, which would indicate a negative year-over-year growth rate of 25.9%. The business is scheduled to announce its next earnings results on Thursday, July 29th.

On average, analysts expect that Travere Therapeutics will report full-year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.45) to ($2.87). For the next financial year, analysts expect that the firm will post earnings of ($3.14) per share, with EPS estimates ranging from ($3.64) to ($2.00). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, May 6th. The company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.40). Travere Therapeutics had a negative net margin of 113.21% and a negative return on equity of 75.08%. The business had revenue of $47.41 million for the quarter, compared to analyst estimates of $49.99 million.

A number of brokerages have commented on TVTX. Barclays cut their price objective on shares of Travere Therapeutics from $40.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, May 26th. Wedbush lowered shares of Travere Therapeutics from an “outperform” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research note on Wednesday, May 26th. Evercore ISI cut their target price on shares of Travere Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 26th. Canaccord Genuity cut their target price on shares of Travere Therapeutics from $48.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, May 24th. Finally, SVB Leerink restated a “buy” rating on shares of Travere Therapeutics in a research note on Sunday, June 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Travere Therapeutics has an average rating of “Buy” and an average price target of $32.71.

In related news, CEO Eric M. Dube sold 9,562 shares of the business’s stock in a transaction dated Wednesday, June 2nd. The shares were sold at an average price of $14.62, for a total transaction of $139,796.44. 4.31% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Penserra Capital Management LLC bought a new position in Travere Therapeutics in the 4th quarter worth about $31,000. Altshuler Shaham Ltd bought a new position in Travere Therapeutics in the 1st quarter worth about $36,000. Exane Derivatives bought a new position in Travere Therapeutics in the 1st quarter worth about $43,000. Pacer Advisors Inc. grew its position in Travere Therapeutics by 48.0% in the 1st quarter. Pacer Advisors Inc. now owns 2,293 shares of the company’s stock worth $57,000 after purchasing an additional 744 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in Travere Therapeutics in the 4th quarter worth about $98,000.

TVTX stock traded down $0.34 during trading on Friday, reaching $13.40. The stock had a trading volume of 10,426 shares, compared to its average volume of 703,376. Travere Therapeutics has a 1-year low of $13.24 and a 1-year high of $33.09. The company has a debt-to-equity ratio of 0.60, a current ratio of 6.65 and a quick ratio of 6.56. The firm has a market capitalization of $810.16 million, a P/E ratio of -3.16 and a beta of 0.67. The company has a fifty day moving average of $15.42.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

See Also: dividend yield calculator

Get a free copy of the Zacks research report on Travere Therapeutics (TVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.